Medical Products

Pemetrexed disodium heptahydrate is chemotherapeutic agent and it falls in the class of anti-metabolites. It is supplied as a sterile lyophilized powder for intravenous infusion available in single-dose vials. Each 100-mg or 500-mg vial of ReliTrexed® contains pemetrexed disodium equivalent to 100 mg pemetrexed or 500 mg.

Pemetrexed is indicated in combination with cisplatin therapy for the initial treatment of patients with locally advanced or metastatic nonsquamous non-small cell lung cancer. It is indicated as a single-agent for the treatment of patients with locally advanced or metastatic nonsquamous non-small cell lung cancer after prior chemotherapy and in combination with cisplatin is indicated for the treatment of patients with malignant mesothelioma whose disease is unresectable or who are otherwise are not candidates for curative surgery.

ReliTrexed® is available in 100 and 500 mg vials.